PharmaJet and Mundipharma have inked an exclusive partnership to market and distribute PharmaJet’s Tropis and Stratis needle-free drug-delivery devices to more than 120 markets around the world.
The devices are designed for vaccine immunizations. PharmaJet has a multi-year agreement with the World Health Organization to provide its needle-free technology for use in the global effort to eradicate polio.
The Tropis device has been shown in multiple studies to deliver a superior immune response as well as mass-scale fractional dose poliovirus vaccine injections at a lower cost than intramuscular injections.
In a statement, Mundipharma CEO, Raman Singh, said the aim of the partnership is to provide access to PharmaJet’s unique needle-free injection technology to more patients, particularly in the emerging world where outbreaks typically occur, and availability and cost can be a barrier to vaccinations.
“Distributing PharmaJet’s needle-free technology aligns well with our aim to provide access to innovative, cost-effective, and safe solutions for the healthcare providers and patients who need it the most,” he added.
Ron Lowy, chairman and CEO of PharmaJet, said Mundipharma’s global network provides the commercial expertise to broaden and accelerate the company’s expansion of needle-free devices within emerging markets.
“We look forward to working together to drive our efforts with health ministries to improve polio, MMR and influenza vaccinations across the emerging world,” he added.
Healthios Capital Markets, a U.S. life sciences investment-banking boutique, advised PharmaJet on the distribution agreement with Mundipharma.
